简介：

简介：Objective:Anti-angiogenicdrugsareanemergingtreatmentoptionagainstmalignanttumors.Theaimofthisstudywastodeterminewhethertheadditionofperioperativerh-endostatintochemotherapycouldimprovetheprobabilityofdistantmetastasis-freesurvival(DMFS)andoverallsurvival(OS)inpatientsnewlydiagnosedwithnon-metastaticconventionalosteosarcoma.Methods:Thiswasacontrollednon-randomizedclinicalstudythatincluded388patientswithoutclinicallydetectablemetastaticdiseaseenrolledfromJanuary2008toApril2012.Thecontroltreatmentgrouphad272patients;180weremaleand92,female,withamedianageof17years.Thetreatmentgrouphad58patients;36weremaleand22,female,withamedianageof16years.Thecontrolgroupreceivedpreoperativechemotherapyfollowedbysurgeryandpostoperativechemotherapy.Thetreatmentgroupreceived4cyclesofrh-endostatinperioperativelyinadditiontochemotherapyasperthecontrolgroup.Patientswerefollowedupfrom6-101monthswithamedianfollow-upperiodof50.2months.Results:The5-yearDMFSofthecontrolgroup(61%)wassignificantlylowerthanthatoftherh-endostatingroup(79%)(P=0.013).The5-yearOSofthecontrolgroup(74%)wassignificantlylowerthanthatoftherh-endostatintreatmentgroup(87%)(P=0.029).Nodifferenceinadversedrugreactionswasfoundbetweenthese2groups.Conclusions:Theadditionofperioperativerh-endostatintochemotherapycouldsignificantlyimprovetheDMFSandOSofpatientswithnon-metastaticosteosarcoma.

简介：